






PatientID: HIVDR-795-23

Sebuttemba 27, 2023

Color Code

 HR: High-Level Resistance  PLR: Potential Low-Level Resistance
 LR: Low-Level Resistance  IR: Intermediate Resistance
 S: Susceptible

| DRUG.CLASS | DRUG | RESISTANCE.PROFILE | DRMS.above.20.percent.prevalence |
|------------|------|--------------------|----------------------------------|
| PI | ATV | S | |
| | DRV | S | |
| | FPV | S | |
| | IDV | S | |
| | LPV | S | |
| | NFV | S | |
| | SQV | S | |
| | TPV | S | |
| NRTI | ABC | S | |
| | AZT | S | |
| | D4T | S | |
| | DDI | S | |
| | FTC | S | |
| | LMV | S | |
| | TDF | S | |
| NNRTI | DOR | HR | M230L;K103N |
| | EFV | HR | |
| | ETR | IR | |
| | NVP | HR | |
| | RPV | HR | |
| INSTI | BIC | S | |
| | CAB | S | |
| | DTG | S | |
| | EVG | S | |
| | RAL | S | |

Appendix

Drug abbreviations in full

| DRUG.CLASS | ABBREVIATION | DRUG.NAME |
|--------------|--------------|----------------|
| PI | ATV | Atazanavir |
| | DRV | Darunavir |
| | FPV | Fosamprenavir |
| | IDV | Indinavir |
| | LPV | Lopinavir |
| | NFV | Nelfinavir |
| | SQV | Saquinavir |
| | TPV | Tipranavir |
| NRTI | ABC | Abacavir |
| | AZT | Azidothymidine |
| | DFT | Stavudine |
| | DDI | Didanosine |
| | FTC | Emtricitabine |
| | LMV | Lamivudine |
| | TDF | Tenofovir |
| NNRTI | DOR | Doravirine |
| | EFV | Efavirenz |
| | ETR | Etravirine |
| | NVP | Nevirapine |
| | RPV | Rilpivirine |
| INSTI | BIC | Bictegravir |
| | CAB | Cabotegravir |
| | DTG | Dolutegravir |
| | EVG | Elvitegravir |
| | RAL | Raltegravir |

Comments

| DRUG.CLASS | COMMENTS |
|--------------|---|
| PI | |
| NRTI | |
| NNRTI | K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM. |
| | M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs. |
| INSTI | |